What is Scholar Rock?
Scholar Rock operates as a specialized biopharmaceutical entity focused on the discovery and development of transformative medicines. The company distinguishes itself through a deep scientific commitment to understanding the molecular basis of disease, particularly in areas where traditional therapeutic options have proven insufficient. By targeting specific protein growth factors, the firm aims to address the underlying pathology of serious conditions, positioning itself as a high-value innovator within the global life sciences ecosystem.
The company's market position is bolstered by a sophisticated investor base that includes top-tier venture capital firms and institutional asset managers. This financial backing provides the necessary runway to transition from early-stage research into advanced clinical trials, effectively bridging the gap between laboratory innovation and patient-centric healthcare solutions.
How much funding has Scholar Rock raised?
Scholar Rock has raised a total of $726M across 8 funding rounds:
Series A
$20M
Series B
$36M
Series C
$47M
Stock Offering
$86.3M
Stock Offering
$51.8M
Debt
$50M
Stock Offering
$230M
Stock Offering
$205M
Series A (2014): $20M with participation from EcoR1 Capital, Polaris Partners, ARCH Ventures, Timothy Springer, and The Kraft Group
Series B (2016): $36M led by ARCH Venture Partners, EcoR1 Capital, Timothy Springer, Fidelity Management and Research Company, The Kraft Group, Cormorant Asset Management, and Polaris Partners
Series C (2018): $47M supported by ARCH Venture Partners, Timothy Springer, Redmile Group, The Kraft Group, EcoR1 Capital, Polaris Partners, Cormorant Asset Management, Invus, and Fidelity Management and Research Company
Stock Issuance/Offering (2018): $86.3M featuring Undisclosed
Stock Issuance/Offering (2019): $51.8M backed by Undisclosed
Debt (2020): $50M with participation from Oxford Finance and Silicon Valley Bank
Stock Issuance/Offering (2020): $230M led by Undisclosed
Stock Issuance/Offering (2022): $205M, investors not publicly disclosed
Key Investors in Scholar Rock
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs.
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector, dedicated to advancing therapeutic innovation and developing new medicines.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing coaching and resources for growth.
What's next for Scholar Rock?
With the recent strategic investment of $205M, Scholar Rock is well-positioned to accelerate its clinical development programs. The firm is expected to prioritize the advancement of its lead candidates through pivotal trials, while simultaneously expanding its research capabilities to explore new therapeutic targets. As the company matures, the focus will likely shift toward regulatory milestones and potential commercialization strategies, supported by the continued guidance of its long-term financial partners.
The strategic roadmap suggests a continued emphasis on operational excellence and scientific rigor. By maintaining a disciplined approach to capital allocation, Scholar Rock aims to solidify its status as a leader in the biopharmaceutical industry, ultimately delivering long-term value to both its stakeholders and the patient populations it serves.
